ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Takanori Ayabe, Masaki Tomita, Kunihide Nakamura
Background: This retrospective study was to evaluate the efficacy and toxicity of gemcitabine plus carboplatin (GC regimen) and paclitaxel plus carboplatin (PC regimen) combination chemotherapy administered as an adjuvant therapy after complete resection of n…
José Pablo Leone, Ricardo H. Álvarez
The development of resistance to chemotherapy, endocrine therapy and anti HER2 agents in breast cancer is an important and common problem that impacts in the management of patients, particularly in the metastatic setting. This resistance has been explained in…
Sreekanth Donepudi, Susan A. Reisinger, John R. McGregor, Shweta Tharkar, Suzanne Samlowski, Daniel Ostler, Shirley Shen, Wolfram E. Samlowski
Metastatic Merkel Cell carcinoma (MCC) is a highly unusual and aggressive skin cancer that presents as a small, pink to violet skin lesion and metastasizes early in its growth. Metastatic MCC is generally treated with small cell lung cancer chemotherapy regim…
Carmen Viada Gonzalez, Jean-François Dupuy, Martha Fors López, Patricia Lorenzo Luaces, Camilo Rodríguez Rodríguez, Gisela González Marinello, Elia Neninger Vinagera, Beatriz García Verdecia, Bárbara Wilkinson Brito, Liana Martínez Pérez, Mayelin Troche de la Concepción, Tania Crombet-Ramos
Background: The Center of Molecular Immunology (CIM) is a center in Cuba devoted to the research, development and manufacturing of biotechnological products. CIMAvax ? EGF is a vaccine for the treatment of non-small cell lung cancer patients (NSCL). Purpose:…
Karima Oualla, Fatimazahra El’mrabet, Hind Elfatemi, Samia Arifi, Nawfel Mellas, Abdelaziz Banani, Siham Tizniti, Afaf Amarti, Omar Elmesbahi
Melanoma of the vagina is a rare lesion. It results from the malignant transformation of ectopic melanocytes occurring in post-menopause. The CKIT is expressed in 36% of cases in addition to melanoma markers. Prognosis is poor especially for inoperable and di…
Kayoko Kawakami, Hiroshi Nishida, Naoto Tatewaki, Kiyomi Eguchi-Kasai, Kazunori Anzai, Takahiro Eitsuka, Tetsuya Konishi, Masao Hirayama
The c ell cycle checkpoint system play a pivotal role in the cellular DNA damage response, and the discovery of check point inhibitors is expected to sensitize current cancer therapies. Checkpoint signaling cascades are critically modulated by ATM (ataxia tel…
Steven Sorscher
Pancreatic poorly differentiated neuroendocrine tumors (PDNETs) are a subtype of neuroendocrine Tumors (NETs) clinically distinguished by their much more rapid growth and immunohistochemically diagnosed by having a higher Ki-67 cancer cell staining percentage…
Shuang Huang, Yonghong Zhang
A 10-year-old boy had a long time of fever, and was diagnosed as JRA at first, but the patient’s condition got worse and worse after the treatment, then we did the cervical lymph node biopsy, which showed ALCL (Anaplastic Large Cell Lymphoma). After receiving…
V. Broshtilova, M. Balabanova
Tyrosine kinase inhibitors (TKI) targeting the bcr-abl protein, c-kit and the platelet-derived growth factor receptors, are significant part of the pathogenic therapy of chronic myelogenous leukemia. A broad spectrum of cutaneous side effects ha s been descri…
Anneli Dowler Nygaard, Karen-Lise Garm Spindler, Niels Pallisgaard, Rikke Fredslund Andersen, Anders Jakobsen
Background: Cell-free DNA (cfDNA) holds promise as a tumor marker of clinical importance. We aimed to investi gate the prognostic value of baseline cfDNA in non small-cell lung cancer (NSCLC). Material and Methods: During a three-year period, patients with ne…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).